Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Thomas Joseph Pugh

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-Radiation Oncology

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Martin GV, Pugh TJ, Mahmood U, Kudchadker RJ, Wang J, Bruno TL, Bathala T, Frank SJ. Permanent prostate brachytherapy pubic arch evaluation with diagnostic MRI. Brachytherapy. 2017 Mar 08. PMID: 28284511.
      View in: PubMed
    2. Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ. Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. Urol Oncol. 2017 Feb 14. PMID: 28214281.
      View in: PubMed
    3. Pugh TJ, Pokharel SS. MRI in prostate brachytherapy: Evidence, clinical end points to data, and direction forward. Brachytherapy. 2017 Feb 01. PMID: 28161432.
      View in: PubMed
    4. Rusthoven CG, Jones BL, Kavanagh BD, Pugh TJ. Reply to J.B. Aragon-Ching and D. Dalela et al. J Clin Oncol. 2017 Mar 10; 35(8):916-917. PMID: 27937090.
      View in: PubMed
    5. Hoffman KE, Skinner H, Pugh TJ, Voong KR, Levy LB, Choi S, Frank SJ, Lee AK, Mahmood U, McGuire SE, Schlembach PJ, Du W, Johnson J, Kudchadker RJ, Kuban DA. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial. Am J Clin Oncol. 2016 Sep 15. PMID: 27635624.
      View in: PubMed
    6. Bian SX, Kuban DA, Levy LB, Oh J, Choi S, McGuire SE, Frank SJ, Mahmood U, Nguyen PL, Pugh TJ, Lee AK, Hoffman KE. The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. Am J Clin Oncol. 2016 Aug; 39(4):368-73. PMID: 24732810.
      View in: PubMed
    7. Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016 Aug 20; 34(24):2835-42. PMID: 27325855.
      View in: PubMed
    8. Lim TY, Kudchadker RJ, Wang J, Bathala T, Szklaruk J, Pugh TJ, Mahmood U, Ibbott GS, Frank SJ. Development of a magnetic resonance imaging protocol to visualize encapsulated contrast agent markers in prostate brachytherapy recipients: initial patient experience. J Contemp Brachytherapy. 2016 Jun; 8(3):235-42. PMID: 27504133.
      View in: PubMed
    9. Grant SR, Walker GV, Koshy M, Shaitelman SF, Klopp AH, Frank SJ, Pugh TJ, Allen PK, Mahmood U. Impact of Insurance Status on Radiation Treatment Modality Selection Among Potential Candidates for Prostate, Breast, or Gynecologic Brachytherapy. Int J Radiat Oncol Biol Phys. 2015 Dec 01; 93(5):968-75. PMID: 26452570.
      View in: PubMed
    10. Pugh TJ, Lee AK. Proton beam therapy for the treatment of prostate cancer. Cancer J. 2014 Nov-Dec; 20(6):415-20. PMID: 25415688.
      View in: PubMed
    11. Pugh TJ, Mahmood U, Swanson DA, Munsell MF, Wang R, Kudchadker RJ, Bruno TL, Frank SJ. Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil. Brachytherapy. 2015 Mar-Apr; 14(2):160-5. PMID: 25255712.
      View in: PubMed
    12. Zhu XR, Poenisch F, Li H, Zhang X, Sahoo N, Wu RY, Li X, Lee AK, Chang EL, Choi S, Pugh T, Frank SJ, Gillin MT, Mahajan A, Grosshans DR. A single-field integrated boost treatment planning technique for spot scanning proton therapy. Radiat Oncol. 2014 Sep 11; 9:202. PMID: 25212571.
      View in: PubMed
    13. Haque W, Wages C, Zhu XR, Choi S, Pugh TJ, Frank SJ, Lee A, Mahmood U. Proton therapy for seminoma: Case report describing the technique, efficacy, and advantages of proton-based therapy for seminoma. Pract Radiat Oncol. 2015 Mar-Apr; 5(2):135-40. PMID: 25413401.
      View in: PubMed
    14. Thaker NG, Kudchadker RJ, Swanson DA, Albert JM, Mahmood U, Pugh TJ, Boehling NS, Bruno TL, Prestidge BR, Crook JM, Cox BW, Potters L, Moran BJ, Keyes M, Kuban DA, Frank SJ. Establishing high-quality prostate brachytherapy using a phantom simulator training program. Int J Radiat Oncol Biol Phys. 2014 Nov 01; 90(3):579-86. PMID: 25151539.
      View in: PubMed
    15. Pugh TJ, Yu W, Yang J, Field AL, Ambrogio L, Carter SL, Cibulskis K, Giannikopoulos P, Kiezun A, Kim J, McKenna A, Nickerson E, Getz G, Hoffher S, Messinger YH, Dehner LP, Roberts CW, Rodriguez-Galindo C, Williams GM, Rossi CT, Meyerson M, Hill DA. Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences. Oncogene. 2014 Nov 06; 33(45):5295-302. PMID: 24909177.
      View in: PubMed
    16. Wang J, Kudchadker R, Choi S, Pettaway CA, Choi H, Hobbs BD, Occena MC, McGuire SE, Pugh TJ, Hoffman K, Mahmood U, Kuban DA. Local recurrence map to guide target volume delineation after radical prostatectomy. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):e239-46. PMID: 25407875.
      View in: PubMed
    17. Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Takiar V, Choi S, Du W, Frank SJ, Johnson J, Kanke J, Kudchadker RJ, Lee AK, Mahmood U, McGuire SE, Kuban DA. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1074-84. PMID: 24661661.
      View in: PubMed
    18. Duzkale H, Shen J, McLaughlin H, Alfares A, Kelly MA, Pugh TJ, Funke BH, Rehm HL, Lebo MS. A systematic approach to assessing the clinical significance of genetic variants. Clin Genet. 2013 Nov; 84(5):453-63. PMID: 24033266.
      View in: PubMed
    19. Pugh TJ, Munsell MF, Choi S, Nguyen QN, Mathai B, Zhu XR, Sahoo N, Gillin M, Johnson JL, Amos RA, Dong L, Mahmood U, Kuban DA, Frank SJ, Hoffman KE, McGuire SE, Lee AK. Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Dec 01; 87(5):946-53. PMID: 24139077.
      View in: PubMed
    20. Mahmood U, Pugh T, Frank S, Levy L, Walker G, Haque W, Koshy M, Graber W, Swanson D, Hoffman K, Kuban D, Lee A. Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy. 2014 Mar-Apr; 13(2):157-62. PMID: 24050892.
      View in: PubMed
    21. Cerne JZ, McGuire SE, Grant SR, Munsell MF, Lee AK, Kudchadker RJ, Choi SL, Mahmood U, Hoffman KE, Pugh TJ, Frank SJ, Kuban DA. Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):346-51. PMID: 23939133.
      View in: PubMed
    22. Nguyen QN, Levy LB, Lee AK, Choi SS, Frank SJ, Pugh TJ, McGuire S, Hoffman K, Kuban DA. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer. 2013 Sep 15; 119(18):3265-71. PMID: 23798338.
      View in: PubMed
    23. Pugh TJ, Amos RA, John Baptiste S, Choi S, Nhu Nguyen Q, Ronald Zhu X, Palmer MB, Lee AK. Multifield optimization intensity-modulated proton therapy (MFO-IMPT) for prostate cancer: Robustness analysis through simulation of rotational and translational alignment errors. Med Dosim. 2013; 38(3):344-50. PMID: 23747223.
      View in: PubMed
    24. Takiar V, Pugh TJ, Swanson D, Kudchadker RJ, Bruno TL, McAvoy S, Mahmood U, Frank SJ. MRI-based sector analysis enhances prostate palladium-103 brachytherapy quality assurance in a phase II prospective trial of men with intermediate-risk localized prostate cancer. Brachytherapy. 2014 Jan-Feb; 13(1):68-74. PMID: 23669149.
      View in: PubMed
    25. Pugh TJ, Nguyen BN, Kanke JE, Johnson JL, Hoffman KE. Radiation therapy modalities in prostate cancer. J Natl Compr Canc Netw. 2013 Apr 01; 11(4):414-21. PMID: 23584344.
      View in: PubMed
    26. Register SP, Kudchadker RJ, Levy LB, Swanson DA, Pugh TJ, Bruno TL, Frank SJ. An MRI-based dose--reponse analysis of urinary sphincter dose and urinary morbidity after brachytherapy for prostate cancer in a phase II prospective trial. Brachytherapy. 2013 May-Jun; 12(3):210-6. PMID: 23466360.
      View in: PubMed
    27. Brown AP, Pugh TJ, Swanson DA, Kudchadker RJ, Bruno TL, Christensen EN, van Vulpen M, Frank SJ. Improving prostate brachytherapy quality assurance with MRI-CT fusion-based sector analysis in a phase II prospective trial of men with intermediate-risk prostate cancer. Brachytherapy. 2013 Sep-Oct; 12(5):401-7. PMID: 23380383.
      View in: PubMed
    28. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):e39-46. PMID: 23102837.
      View in: PubMed
    29. Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys. 2013 Mar 01; 85(3):693-9. PMID: 22836052.
      View in: PubMed
    30. Pugh TJ, Choi S, Nguyen QN, Gillin MT, Ron Zhu X, Palmer MB, Lee AK. Proton beam therapy for the treatment of prostate cancer. Pract Radiat Oncol. 2013 Apr-Jun; 3(2):e87-94. PMID: 24674325.
      View in: PubMed
    31. Albert JM, Swanson DA, Pugh TJ, Zhang M, Bruno TL, Kudchadker RJ, Frank SJ. Magnetic resonance imaging-based treatment planning for prostate brachytherapy. Brachytherapy. 2013 Jan-Feb; 12(1):30-7. PMID: 22727474.
      View in: PubMed
    32. Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, McGuire SE, Swanson DA, Kudchadker R, Davis JW. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy. 2013 May-Jun; 12(3):204-9. PMID: 22673704.
      View in: PubMed
    33. Kudchadker RJ, Pugh TJ, Swanson DA, Bruno TL, Bolukbasi Y, Frank SJ. Preoperative treatment planning with intraoperative optimization can achieve consistent high-quality implants in prostate brachytherapy. Med Dosim. 2012; 37(4):387-90. PMID: 22560295.
      View in: PubMed
    34. Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE. Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol. 2012 Sep; 23(9):2346-52. PMID: 22357249.
      View in: PubMed
    35. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer. 2012 Jul; 48(11):1664-71. PMID: 22336663.
      View in: PubMed
    36. Whaley JT, Levy LB, Swanson DA, Pugh TJ, Kudchadker RJ, Bruno TL, Frank SJ. Sexual function and the use of medical devices or drugs to optimize potency after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):e765-71. PMID: 22300559.
      View in: PubMed
    37. Griffith M, Mwenifumbo JC, Cheung PY, Paul JE, Pugh TJ, Tang MJ, Chittaranjan S, Morin RD, Asano JK, Ally AA, Miao L, Lee A, Chan SY, Taylor G, Severson T, Hou YC, Griffith OL, Cheng GS, Novik K, Moore R, Luk M, Owen D, Brown CJ, Morin GB, Gill S, Tai IT, Marra MA. Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer. Pharmacogenomics J. 2013 Apr; 13(2):148-58. PMID: 22249354.
      View in: PubMed
    38. Sharp HJ, Swanson DA, Pugh TJ, Zhang M, Phan J, Kudchadker R, Bruno TL, Kuban DA, Lee AK, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Frank SJ. Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. Pract Radiat Oncol. 2012 Jul-Sep; 2(3):e7-e13. PMID: 24674130.
      View in: PubMed
    39. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J. 2012 Jan-Feb; 18(1):1-8. PMID: 22290249.
      View in: PubMed
    40. Samuelian JM, Swanson DA, Kudchadker RJ, Pugh TJ, Kuban DA, Lee AK, Choi S, Nguyen QN, Bruno TL, Frank SJ. Long-term tumor control after brachytherapy for base-of-prostate cancer. J Contemp Brachytherapy. 2011 Dec; 3(4):183-7. PMID: 23346126.
      View in: PubMed
    41. Pugh TJ, Lee AK. Role of radiation therapy for the treatment of lymph nodes in urologic malignancies. Urol Clin North Am. 2011 Nov; 38(4):497-506, vii. PMID: 22045180.
      View in: PubMed
    42. Frank SJ, Levy LB, van Vulpen M, Crook J, Sylvester J, Grimm P, Pugh TJ, Swanson DA. Outcomes after prostate brachytherapy are even better than predicted. Cancer. 2012 Feb 01; 118(3):839-47. PMID: 21751187.
      View in: PubMed
    43. Pugh TJ, Lee NY, Pacheco T, Raben D. Microcystic adnexal carcinoma of the face treated with radiation therapy: a case report and review of the literature. Head Neck. 2012 Jul; 34(7):1045-50. PMID: 21384456.
      View in: PubMed
    44. Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2010 Aug 15; 116(16):3843-51. PMID: 20564102.
      View in: PubMed
    45. Rusthoven KE, Pugh TJ. Stereotactic body radiation therapy for inoperable lung cancer. JAMA. 2010 Jun 16; 303(23):2354-5; author reply 2355. PMID: 20551403.
      View in: PubMed
    46. Pugh TJ, Chen C, Rabinovitch R, Eckhardt SG, Rusthoven KE, Swing R, Raben D. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. Int J Radiat Oncol Biol Phys. 2010 Oct 01; 78(2):521-6. PMID: 20133082.
      View in: PubMed
    47. Pugh TJ, Ballonoff A, Rusthoven KE, McCammon R, Kavanagh B, Newman F, Rabinovitch R. Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: a surveillance, epidemiology, and end-results analysis. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):845-9. PMID: 19515509.
      View in: PubMed
    48. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009 Apr 01; 27(10):1572-8. PMID: 19255321.
      View in: PubMed
    49. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009 Apr 01; 27(10):1579-84. PMID: 19255320.
      View in: PubMed
    50. Pugh TJ, Gaspar LE. Prophylactic cranial irradiation for patients with lung cancer. Clin Lung Cancer. 2007 May; 8(6):365-8. PMID: 17562236.
      View in: PubMed
    Pugh's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)